adrenal incidentaloma

in review 5 min read Updated 2026-11-19
adrenal incidentaloma

Defined as an adrenal mass ≥1 cm discovered on imaging performed for an unrelated indication. Every evaluation answers two questions: is it malignant? and is it hormonally active? On unenhanced CT, a homogeneous mass with ≤10 HU is benign — no repeat imaging is needed regardless of size and metanephrines are not required. Every patient gets a 1-mg overnight DST; ARR is ordered only if hypertensive or hypokalaemic. Never biopsy an adrenal mass before excluding phaeochromocytoma.

do not miss
  • Biopsy before excluding phaeochromocytoma: can trigger fatal hypertensive crisis — adrenal biopsy is almost never indicated anyway (only if extra-adrenal malignancy is known, biopsy changes management, and phaeo is excluded).
  • Adrenocortical carcinoma (ACC): suspect if ≥4 cm, heterogeneous, unenhanced CT >20 HU, rapid growth, or androgen/oestrogen excess — never biopsy (seeding risk); refer for complete en bloc resection.
  • Perioperative adrenal crisis: patients with MACS (1-mg DST >50 nmol/L) have contralateral adrenal suppression and require perioperative stress-dose glucocorticoids during adrenalectomy.

step 1 — assess malignancy risk (ESE 2023)

Obtain a dedicated unenhanced adrenal CT if not already done (or review unenhanced attenuation on the index scan):

unenhanced CT appearanceinterpretationimaging follow-up / action
homogeneous and ≤10 HUbenign lipid-rich adenomano further imaging (regardless of size; ESE 2023)
homogeneous, 11–20 HU, and <4 cmindeterminate (usually benign lipid-poor adenoma)immediate second-line imaging (FDG-PET/CT, MRI chemical shift, or delayed contrast washout CT) or single repeat unenhanced CT/MRI in 12 months
≥4 cm with 11–20 HU, or <4 cm with >20 HU or heterogeneouslow–intermediate malignancy riskimmediate additional imaging preferred (FDG-PET/CT, MRI chemical shift, or contrast washout CT — rapid washout favours benign adenoma; slow/low delayed washout [<50–60% absolute or <40% relative at 10–15 min] suggests malignancy, though phaeochromocytomas can mimic benign washout)
≥4 cm AND (heterogeneous or >20 HU)high risk of malignancy (ACC, metastasis, phaeo)multidisciplinary review; consider FDG-PET/CT to stage; surgery usually favoured (open if local invasion/ACC suspected)
growth on repeat imaging≥20% increase and ≥5 mm absolute diameter increasesuspicious → consider surgical resection (no change in size → no further imaging; measurable growth below threshold → consider repeat scan in 6–12 months)
  • Known active extra-adrenal malignancy: metastasis is much more likely; use FDG-PET/CT to distinguish metastasis from benign adenoma (skip biopsy unless results will change oncologic therapy and phaeo is excluded)
  • Classic benign non-adenoma lesions (myelolipoma with macroscopic fat, simple cyst): require no further imaging

step 2 — assess hormonal activity (ESE 2023)

hormone axiswho to testscreening testthreshold / action
cortisolall patients1-mg overnight DST≤50 nmol/L excludes autonomous secretion; >50 nmol/L without overt Cushing stigmata = MACS
catecholaminesonly if imaging is not typical of a benign lipid-rich adenoma (>10 HU or heterogeneous)plasma free or 24-h urine fractionated metanephrinesnot needed if homogeneous ≤10 HU (ESE 2023 R3.9); see phaeochromocytoma and paraganglioma
aldosteronehypertension or unexplained hypokalaemiamorning seated ARR (aldosterone + renin)see secondary hypertension for ES 2025 vs HTN Canada 2020 thresholds and AVS
sex steroids / precursorsclinical virilisation/feminisation or imaging suspicious for ACCDHEA-S, androstenedione, testosterone, 17-OHP (or urine steroid metabolomics)elevated precursors support ACC; measure pre-op
  • Bilateral adrenal incidentalomas: evaluate each lesion’s imaging features independently; perform the same hormonal panel plus screen for adrenal insufficiency (if suspected metastases, haemorrhage, lymphoma, or infiltrative disease) and congenital adrenal hyperplasia (17-OHP if bilateral hyperplasia)

mild autonomous cortisol secretion (MACS)

  • Diagnosis (ESE 2023): 1-mg DST cortisol >50 nmol/L in a patient without overt clinical features of cushing syndrome (repeat 1-mg DST once to confirm; confirm ACTH-independence with suppressed/low-normal morning plasma ACTH)
  • Why it matters: associated with increased prevalence of hypertension, type 2 diabetes, dyslipidaemia, osteoporosis/vertebral fractures, cardiovascular events, and mortality
  • Management:
    • Screen all patients with MACS for hypertension, type 2 diabetes, and vertebral fractures (DXA ± spine X-ray/VFA) and treat comorbidities aggressively
    • Surgery vs conservative management: discuss laparoscopic unilateral adrenalectomy in an individualised multidisciplinary setting for patients with relevant cortisol-related comorbidities (especially younger patients or progressive/difficult-to-control HTN, T2DM, or fragility fractures)
    • Perioperative protection: if resected, administer perioperative stress-dose glucocorticoids and taper post-operatively until HPA-axis recovery is confirmed (see adrenal insufficiency)
  • Non-functioning benign adenoma (≤10 HU and normal hormonal workup): no routine repeat hormonal testing unless new clinical signs of hormone excess or worsening comorbidities emerge

surgical indications and biopsy rules

  • Operate for:
  • Approach: laparoscopic adrenalectomy for benign lesions and small non-invasive masses; open adrenalectomy for suspected ACC with local invasion or large invasive tumours (>6 cm) to avoid capsular rupture
  • Adrenal biopsy: contraindicated for routine incidentalomas and suspected ACC; reserve strictly for patients with a history of extra-adrenal malignancy when the mass is indeterminate on imaging, phaeochromocytoma has been excluded, and tissue confirmation will directly alter management

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

Suggest a correction adrenal incidentaloma